2011
Expression of an IRF-3 fusion protein and mouse estrogen receptor, inhibits hepatitis C viral replication in RIG-I-deficient Huh 7.5 cells
Yao L, Yan X, Dong H, Nelson D, Liu C, Li X. Expression of an IRF-3 fusion protein and mouse estrogen receptor, inhibits hepatitis C viral replication in RIG-I-deficient Huh 7.5 cells. Virology Journal 2011, 8: 445. PMID: 21936899, PMCID: PMC3213043, DOI: 10.1186/1743-422x-8-445.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCell LineDEAD Box Protein 58DEAD-box RNA HelicasesGene ExpressionHepacivirusHepatocytesHumansInterferon Regulatory Factor-3Interferon-alphaInterferon-betaMiceProtein BiosynthesisProtein MultimerizationReal-Time Polymerase Chain ReactionReceptors, EstrogenReceptors, ImmunologicRecombinant Fusion ProteinsTranscription, GeneticVirus ReplicationConceptsAnti-HCV effectInterferon regulatory factor 3Huh-7.5 cellsEstrogen receptorPolymerase chain reactionHepatitis C virus infectionViral replicationC virus infectionMouse estrogen receptorHepatitis C viral replicationInterferon-stimulated gene expressionExpression of IFNHCV viral replicationHCV RNA replicationReal-time polymerase chain reactionEstrogen receptor agonistsExpression of ISGsRegulatory factor 3HCV IRES-dependent translation
2010
Characterization of Anti-HCV Antibodies in IL-10-Treated Patients
Eksioglu E, Bess J, Jones G, Dettloff J, Dangmeon P, Dong H, Zhu H, Firpi R, Xu Y, Nelson D, Liu C. Characterization of Anti-HCV Antibodies in IL-10-Treated Patients. Viral Immunology 2010, 23: 359-368. PMID: 20712480, PMCID: PMC2978060, DOI: 10.1089/vim.2009.0095.Peer-Reviewed Original ResearchConceptsAnti-HCV antibodiesAnti-HCV antibody titersIL-10Antibody titersTotal anti-HCV antibodyHepatitis C virus infectionC virus infectionChronic hepatitis patientsIL-10 treatmentReal-time reverse transcriptase-polymerase chain reactionReverse transcriptase-polymerase chain reactionTranscriptase-polymerase chain reactionHuh-7.5 cellsHCV-negative seraAntibody neutralization activityDisease activityHCV antibodiesViral burdenHepatitis patientsViral loadInterleukin-10Antibody responseReplicon cellsPolymerase chain reactionNeutralization antibody
2004
STAT3 induces anti-hepatitis C viral activity in liver cells
Zhu H, Shang X, Terada N, Liu C. STAT3 induces anti-hepatitis C viral activity in liver cells. Biochemical And Biophysical Research Communications 2004, 324: 518-528. PMID: 15474458, DOI: 10.1016/j.bbrc.2004.09.081.Peer-Reviewed Original ResearchMeSH KeywordsAntiviral AgentsBlotting, NorthernBlotting, WesternCarcinoma, HepatocellularCell LineCell Line, TumorCytokinesDNA-Binding ProteinsDose-Response Relationship, DrugEnzyme InhibitorsGenes, DominantHepacivirusHumansInflammationInterferonsInterleukin-6LigandsLiverLiver NeoplasmsLuciferasesPlasmidsProtein Structure, TertiaryReverse Transcriptase Polymerase Chain ReactionRibavirinRNARNA, MessengerSTAT3 Transcription FactorTime FactorsTrans-ActivatorsTransfectionTyrphostinsConceptsAnti-HCV activityInterferon alphaSTAT3 activationHuman hepatoma cellsHepatitis C virus infectionHCV subgenomic RNA replicationMain therapeutic regimenC virus infectionChronic liver diseaseCytokines IL-6Replicon cell linesIntracellular antiviral stateCell linesHepatoma cellsLiver diseaseTherapeutic regimenActivation of STAT3IL-6Virus infectionEstrogen receptorIFN treatmentAntiviral genesAntiviral pathwaysAntiviral activityAntiviral stateAn immunomodulatory role for CD4+CD25+ regulatory T lymphocytes in hepatitis C virus infection
Cabrera R, Tu Z, Xu Y, Firpi R, Rosen H, Liu C, Nelson D. An immunomodulatory role for CD4+CD25+ regulatory T lymphocytes in hepatitis C virus infection. Hepatology 2004, 40: 1062-1071. PMID: 15486925, DOI: 10.1002/hep.20454.Peer-Reviewed Original ResearchMeSH KeywordsAntibodiesAntibody FormationAntigens, CDCase-Control StudiesCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell CommunicationEpitopesHepatitis CHepatitis C AntigensHumansImmune SystemInterleukin-10PhenotypeReceptors, Interleukin-2Transforming Growth Factor betaTransforming Growth Factor beta1ConceptsHepatitis C virus infectionPeripheral blood mononuclear cellsC virus infectionRegulatory T lymphocytesBlood mononuclear cellsT lymphocytesMononuclear cellsVirus infectionHCV-specific T-cell responsesCell-cell contact mannerT cell immune responsesHCV RNA titersT cell frequenciesIL-10 productionT cell responsesCell immune responsesInterferon-gamma productionLiver inflammatory activityNormal control subjectsT cell proliferationInterferon gamma activityGrowth factor betaIL-10Intracellular cytokinesInflammatory activityOne‐year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection
Firpi R, Abdelmalek M, Soldevila‐Pico C, Cabrera R, Shuster J, Theriaque D, Reed A, Hemming A, Liu C, Crawford J, Nelson D. One‐year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transplantation 2004, 10: 1240-1247. PMID: 15376304, DOI: 10.1002/lt.20238.Peer-Reviewed Original ResearchConceptsProtocol liver biopsiesRapid fibrosis progressionLiver transplant recipientsFibrosis progressionDonor ageLiver biopsyTransplant recipientsCytomegalovirus infectionUnits/yearMedian fibrosis progression rateRecurrent hepatitis C infectionHepatitis C virus infectionC virus infectionDevelopment of cirrhosisFibrosis progression rateHepatitis C infectionSurgery-related variablesRate of progressionDevelopment of fibrosisDeterminants of progressionGraft lossKnodell systemRecurrent HCVRejection episodesYear posttransplant
2002
Combination of interferon alfa‐2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C
Firpi R, Abdelmalek M, Soldevila‐Pico C, Reed A, Hemming A, Howard R, van der Werf W, Lauwers G, Liu C, Crawford J, Davis G, Nelson D. Combination of interferon alfa‐2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transplantation 2002, 8: 1000-1006. PMID: 12424712, DOI: 10.1053/jlts.2002.34968.Peer-Reviewed Original ResearchConceptsInterferon alfa-2bLiver transplantationAlfa-2bHistological recurrenceViral eradicationHCV RNAWeek 24Recurrent hepatitis C virus (HCV) infectionHCV RNA 6 monthsHepatitis C virus infectionEnd pointProgressive cholestatic diseaseRecurrent HCV infectionSerum HCV RNAC virus infectionLiver transplant recipientsPrimary end pointRecurrent hepatitis CSecondary end pointsGenotype 1 infectionYears of therapyEnd of treatmentHigh viral loadLiver biopsy resultsRecurrent HCV